US · HOWL
Werewolf Therapeutics, Inc.
Price · as of 2026-10-31
$0.99
Market cap 19.54M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for Werewolf Therapeutics, Inc. (HOWL) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
- CEO
- Daniel J. Hicklin
- Employees
- 14
- Beta
- 0.30
The peer comparison table is shown only to users with a Pro subscription.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.